Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03117309
Title Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Michael B. Atkins, MD
Indications

renal cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.